We are live on ! Find out more
IKT icon

Inhibikase Therapeutics
IKT

47 hedge funds and large institutions have $113M invested in Inhibikase Therapeutics in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

533% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 3

300% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 3

52% more funds holding

Funds holding: 31 → 47 (+16)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5.3% less ownership

Funds ownership: 74.53% → 69.23% (-5.3%)

31% less capital invested

Capital invested by funds: $163M → $113M (-$50M)

Holders
47
Holders Change
+16
Holders Change %
+51.61%
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
12
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.94M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.27M
3
Marshall Wace
Marshall Wace
United Kingdom
+$390K
4
Goldman Sachs
Goldman Sachs
New York
+$307K
5
Jane Street
Jane Street
New York
+$292K

Top Sellers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
-$1.46M
2
SCM
Stonepine Capital Management
Oregon
-$546K
3
Citigroup
Citigroup
New York
-$129K
4
AGM
Alpine Global Management
New York
-$96.5K
5
Squarepoint
Squarepoint
New York
-$92.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCV
1
Sands Capital Ventures
Virginia
$24M – – –
SCM
2
Soleus Capital Management
Connecticut
$13.9M – – –
FFM
3
Fairmount Funds Management
Pennsylvania
$13.4M – – –
PA
4
Perceptive Advisors
New York
$13M – – –
CC
5
Commodore Capital
New York
$11.7M -$1.46M -580,568 -10%
ACM
6
ADAR1 Capital Management
Texas
$11.2M +$48K +19,100 +0.4%
Vanguard Group
7
Vanguard Group
Pennsylvania
$6.24M +$25.2K +10,018 +0.4%
NCM
8
Nantahala Capital Management
Connecticut
$4.8M – – –
Blackstone Inc
9
Blackstone Inc
New York
$4.53M – – –
SCM
10
Stonepine Capital Management
Oregon
$2M -$546K -217,415 -19%
Millennium Management
11
Millennium Management
New York
$2M +$1.94M +771,293 +542%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$1.11M +$1.27M +504,625 New
BlackRock
13
BlackRock
New York
$929K +$222K +88,519 +26%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$711K +$4.73K +1,882 +0.6%
Goldman Sachs
15
Goldman Sachs
New York
$364K +$307K +122,073 +278%
William Blair & Company
16
William Blair & Company
Illinois
$342K +$52.8K +21,000 +16%
Marshall Wace
17
Marshall Wace
United Kingdom
$340K +$390K +155,270 New
Jane Street
18
Jane Street
New York
$255K +$292K +116,249 New
Barclays
19
Barclays
United Kingdom
$184K – – –
Balyasny Asset Management
20
Balyasny Asset Management
Illinois
$178K +$204K +81,161 New
HF
21
HRT Financial
New York
$144K +$49K +19,490 +42%
Northern Trust
22
Northern Trust
Illinois
$140K – – –
OAC
23
OMERS Administration Corp
Ontario, Canada
$123K +$3.52K +1,400 +3%
JG
24
Jain Global
New York
$120K +$138K +54,845 New
UBS Group
25
UBS Group
Switzerland
$99.1K +$44.6K +17,740 +64%
1
2

IKT Hedge Fund Activity: Q1 2025 in Review

47 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q1 2025, worth a combined $113M — down 31% from $163M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new IKT positions and 3 closed out — a net gain of 16 holders — while 12 added to existing stakes and 3 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.94M. The largest seller was Commodore Capital, cutting an estimated $1.46M.

  • 47 institutional investors held Inhibikase Therapeutics (IKT) as of Q1 2025, up from 31 in Q4 2024.
  • Funds reported $113M of Inhibikase Therapeutics stock for Q1 2025, down 31% quarter-over-quarter.
  • 19 funds opened new Inhibikase Therapeutics positions in Q1 2025 and 3 closed out, a net change of +16 holders.
  • The largest Inhibikase Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $1.94M added.
  • The largest Inhibikase Therapeutics seller in Q1 2025 was Commodore Capital, an estimated $1.46M sold.

Based on aggregated 13F filings for Q1 2025.